DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma

This study developed a #Cuproptosis signature and identified DLAT as a novel #Biomarker for #Cancer prognosis and intervention and also demonstrates that #Elesclomol exerts #Anticancer effects through DLAT in a copper-dependent manner. #medsky

Read: link.springer.com/article/10.1...